Meta-Analysis: How Well Do Dual and Triple Incretin Agonists Work for Weight Loss?
A systematic review and meta-analysis evaluates the efficacy and safety of dual and triple incretin agonists for obesity, finding enhanced weight loss through multi-receptor targeting.
Quick Facts
What This Study Found
Incretin-based dual and triple agonists demonstrate enhanced weight loss compared to single-receptor approaches, with the meta-analysis quantifying efficacy and safety across available RCTs.
Key Numbers
How They Did This
Systematic review and meta-analysis of RCTs from PubMed, Cochrane Library, and Google Scholar through June 2025.
Why This Research Matters
Dual and triple agonists represent the next generation of obesity drugs. This meta-analysis provides the first comprehensive pooled evidence on whether targeting more receptors truly translates to better weight loss outcomes.
The Bigger Picture
The obesity pharmacotherapy landscape is rapidly evolving from single-target to multi-target approaches. This analysis helps define how much additional benefit each added receptor target provides.
What This Study Doesn't Tell Us
Limited number of available trials for triple agonists; heterogeneity in study designs and populations; most triple-agonist data from early-phase trials.
Questions This Raises
- ?Do triple agonists provide meaningfully better weight loss than dual agonists to justify potential additional risks?
- ?Which patient populations benefit most from multi-receptor versus single-receptor agonism?
Trust & Context
- Key Stat:
- Dual + triple agonists analyzed First comprehensive meta-analysis pooling RCT data on multi-receptor incretin drugs for obesity
- Evidence Grade:
- Systematic review and meta-analysis of RCTs — highest level of evidence synthesis, though limited by available primary study data.
- Study Age:
- Published in 2026 with literature through June 2025, capturing the most current trial data on emerging multi-agonist drugs.
- Original Title:
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
- Published In:
- Cardiology in review (2026)
- Authors:
- Chan, Zhi Hong, Omar, Abdousamad Said, Gill, Kieran, Volucke, Gabriele, Azhar, Muhammad Muneeb, Haleem, Syed Mohammad, Sia, Jian En, Rahman, Obaid Ur, Ahmad, Moaz, Shahid, Nuraan, Gardezi, Syed Anjum, Joseph, Kevin Vinod, Behary Paray, Nitish, Zulfiqar, Eeshal
- Database ID:
- RPEP-14958
Evidence Hierarchy
Frequently Asked Questions
What are dual and triple incretin agonists?
Dual agonists (like tirzepatide) activate two hormone receptors (GLP-1 and GIP), while triple agonists add a third target (glucagon receptor). More targets may produce greater weight loss but could also increase side effects.
Are triple agonists better than dual agonists for weight loss?
This meta-analysis examines that question by pooling all available trial data. While multi-receptor targeting shows enhanced efficacy, the optimal balance of benefits and risks is still being determined.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14958APA
Chan, Zhi Hong; Omar, Abdousamad Said; Gill, Kieran; Volucke, Gabriele; Azhar, Muhammad Muneeb; Haleem, Syed Mohammad; Sia, Jian En; Rahman, Obaid Ur; Ahmad, Moaz; Shahid, Nuraan; Gardezi, Syed Anjum; Joseph, Kevin Vinod; Behary Paray, Nitish; Zulfiqar, Eeshal. (2026). Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000001209
MLA
Chan, Zhi Hong, et al. "Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.." Cardiology in review, 2026. https://doi.org/10.1097/CRD.0000000000001209
RethinkPeptides
RethinkPeptides Research Database. "Incretin-Based Dual and Triple Agonists in Overweight or Obe..." RPEP-14958. Retrieved from https://rethinkpeptides.com/research/chan-2026-incretinbased-dual-and-triple
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.